Who are IBI363's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AK104(IV), IBI310, BAT2306, BAT5906 injection, BAT2506 injection, AK102.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibi363.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

IBI363 — Competitive Intelligence Brief

IBI363 (IBI363) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific checkpoint inhibitor. Area: Oncology.

phase 3 Bispecific checkpoint inhibitor PD-1 and TIM-3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IBI363 (IBI363) — Innovent Biologics (Suzhou) Co. Ltd.. IBI363 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IBI363 TARGET	IBI363	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3
AK104(IV)	AK104(IV)	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3
IBI310	IBI310	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3
BAT2306	BAT2306	Bio-Thera Solutions	phase 3	Bispecific checkpoint inhibitor
BAT5906 injection	BAT5906 injection	Bio-Thera Solutions	phase 3	Bispecific checkpoint inhibitor
BAT2506 injection	BAT2506 injection	Bio-Thera Solutions	phase 3	Bispecific checkpoint inhibitor
AK102	AK102	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific checkpoint inhibitor class)

Akeso · 3 drugs in this class
Bio-Thera Solutions · 3 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 2 drugs in this class
Fujifilm Kyowa Kirin Biologics Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IBI363 — Competitive Intelligence Brief. https://druglandscape.com/ci/ibi363. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab